Co-delivery of doxorubicin/sorafenib by DNA-decorated green ZIF-67-based nanocarriers for chemotherapy and hepatocellular carcinoma treatment

Environ Res. 2023 May 15:225:115589. doi: 10.1016/j.envres.2023.115589. Epub 2023 Feb 27.

Abstract

Zeolitic imidazolate framework-67 (ZIF-67) has been decorated with natural biomaterials and DNA to develop a promising strategy and suitable and safe co-delivery platform for doxorubicin and sorafenib (DOX-SOR). FT-IR, XRD, FESEM, and TEM were used to characterize the modified MOFs. Combined Ginkgo biloba leaf extract and E. coli DNA were used as green decorations, and as environmentally-friendly methods to be developed, and DOX and SOR were attached to the porosity and on the surface of the MOFs. TEM and FESEM images demonstrated that the green MOFs were successfully synthesized for biomedical applications and showed their cubic structure. As a result of the nanocarrier-drug interactions, 59.7% and 60.2% of the drug payload were achieved with DOX and SOR, respectively. HEK-293, HT-29, and MCF-7 cells displayed excellent viability by decoration with DNA and Ginkgo biloba leaf extract at low and high concentrations (0.1 and 50 μg/mL), suggesting they could be used in biomedical applications. MTT assays demonstrated that the nanocarriers are highly biocompatible with normal cells and possess anticancer properties when applied to HT-29 and MCF-7 cells. As a result of Ginkgo biloba leaf extract and DNA modification, DOX-SOR release was prolonged and pH-sensitive (highest release at pHs 4.5 and 5.5). The internalization and delivery of the drug were also studied using a 2d fluorescence microscope, demonstrating that the drug was effectively internalized. Cell images showed NPs internalizing in MCF-7 cells, proving their efficacy as drug delivery systems.

Keywords: Co-drug delivery; Doxorubicin; Green chemistry; Sorafenib.; ZIF-67.

MeSH terms

  • Carcinoma, Hepatocellular* / drug therapy
  • Doxorubicin / chemistry
  • Doxorubicin / pharmacology
  • Escherichia coli
  • HEK293 Cells
  • Humans
  • Liver Neoplasms* / drug therapy
  • Nanoparticles* / chemistry
  • Sorafenib / therapeutic use
  • Spectroscopy, Fourier Transform Infrared

Substances

  • Sorafenib
  • Doxorubicin